A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-Week Cycle in Patients With Advanced Malignancies.

Trial Profile

A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-Week Cycle in Patients With Advanced Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs Pracinostat (Primary) ; Azacitidine
  • Indications Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 25 Aug 2017 Results published in the Cancer.
    • 02 Dec 2014 Results from the phase I portion in elderly patients with acute myeloid leukaemia published in an MEI Pharma media release.
    • 19 Dec 2012 Results from the phase II part in patients with myelodysplastic syndromes were presented at the 54th Annual Meeting of the American Society of Hematology according to a MEI Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top